Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug protect failing kidneys?

NCT ID NCT05309785

Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study looks at whether canagliflozin, a drug used for diabetes, can safely reduce protein in the urine (a sign of kidney damage) in people with advanced chronic kidney disease (CKD), including those on dialysis. About 35 adults with CKD stage 4 or 5 will take the drug for up to 26 weeks. The goal is to see if it helps protect the kidneys without causing serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

34 people

The number who actually took part.

Started

Nov 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (Substudy 1- SIP-AKiD-1): * adult patients with eGFR \<30 ml/min/1.73m2 * urine albumin to creatinine ratio (UACR) \>200 mg/g * not receiving dialysis. (Substudy 2- SIP-AKiD-2): * adult patients on hemodialysis for at least 3 months * without significant residual renal function, defined as a urine output \<250 ml/24h. Exclusion Criteria: * Age \<18 years * type 1 diabetes * history of euglycemic ketoacidosis * known hypersensitivity to SGLT-2 inhibitors * recurrent severe genital or urinary tract infections * history of atraumatic amputation, gangrene, or active skin ulcer * use within the last 48 h of an SGLT-2 inhibitor or a combined SGLT-1 and SGLT-2 inhibitor * liver disease defined by an ALT \> 3.0 times the upper limit of normal \[ULN\] or total bilirubin \>1.5 times the ULN or liver cirrhosis of any stage * gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption * pregnancy * currently breastfeeding * any other clinical condition that would jeopardize patient safety while participating in this trial. * Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir will be excluded if these agents cannot be safely discontinued

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD stage 4 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD stage 4 CKD stage 5 ESRD

Contacts and locations

Locations

  • McGill University Health Center

    Montreal, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.